Special Issue "Next-Generation Vaccines and Antivirals against SARS-CoV-2"
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 5990
Interests: molecular virology and oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Viruses: The Inflammasomes - Key Players in Antiviral Response
The ongoing pandemic of COVID-19 is still rapidly evolving, with an endemic tendency already in sight. Existing vaccines against SARS-CoV-2, particularly mRNA and adenoviral vectored vaccines, are highly efficacious in preventing severe disease and hospitalization. However, they are less effective in blocking transmission, and as a result, breakthrough infections are more common than expected. Historically, eradication of smallpox virus and near-eradication of poliovirus from humans relied on live attenuated vaccines that can elicit mucosal and sterilizing immunity. This should be our next goal in the development of SARS-CoV-2 vaccines. In addition to live attenuated vaccines, single-cell vaccines and replication-defective vaccines might also have their own merits worthy of further exploration. On the other hand, newly discovered antivirals against SARS-CoV-2, including a nucleoside analog and a protease inhibitor, exhibit high capability in blocking SASR-CoV-2 replication. They provide new weapons to combat COVID-19 and have just begun to bring benefits to more patients with severe COVID-19. It is expected that additional new and repurposed therapeutic agents will be available in the coming months. This Special Issue will provide an outlet for exciting original research papers and high-quality reviews focusing on next-generation vaccines and antivirals against SARS-CoV-2. This collection of papers and reviews will provide a snapshot of the current research efforts and accomplishments, from which new thoughts and strategies will be developed toward putting an end to the pandemic.
Prof. Dr. Dong-Yan Jin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mRNA vaccine
- live attenuated vaccine
- single-cycle vaccine
- replication-defective vaccine
- booster vaccination
- mucosal immunity
- sterilizing immunity
- neutralizing antibodies
- nucleoside analog
- cytotoxic T lymphocyte
- secretary immunoglobulin A